Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents

Gary S. Mintz, Myeong Ki Hong, Albert E. Raizner, Cheol Whan Lee, Jae Joong Kim, Esteban Escolar, Neal E. Fearnot, Seong Wook Park, Seung Jung Park, Neil J. Weissman

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Using data from the ASian Paclitaxel-Eluting Stent Clinical Trial, a 3-center, randomized, placebo-controlled trial of nonpolymeric paclitaxel-coated stents with a single center, 81-patient intravascular ultrasound (IVUS) substudy, the length of a stent that was free of IVUS-detectable intimal hyperplasia measured 3.2 ± 4.8 mm in placebo stents, 6.1 ± 5.6 mm in low-dose stents, and 8.7 ± 6.1 mm in high-dose stents (p = 0.0029). IVUS percent neointima volume obstruction correlated with the length of this IVUS neointima-free segment (r = 0.785, p <0.0001); angiographic late lumen loss and follow-up diameter stenosis also correlated with the IVUS neointima-free length of the stents (r = 0.670, p <0.0001 and r = 0.679, p <0.0001, respectively.

Original languageEnglish
Pages (from-to)107-109
Number of pages3
JournalAmerican Journal of Cardiology
Volume95
Issue number1
DOIs
Publication statusPublished - 2005 Jan 1

Bibliographical note

Funding Information:
This study was supported by the Cardiovascular Research Foundation, Seoul, Korea, and Cook Incorporated, Bloomington, Indiana.

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents'. Together they form a unique fingerprint.

Cite this